Aktuelle Aspekte der Chemotherapie in der ­gastroenterologischen Onkologie

Literatur

• 1 Cassidy J, Twelves C, Van Cutsem E. et al . First-line oral capacitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with i. v. 5-fluorouracil/leucovorin.  Ann Oncol. 2002;  13 566-575
• 2 Tabernero J, Butts C A, Cassidy J. et al . Capecitabine and oxaliplatin in combination (Xelox) as first line therapy for patients (pts) with metastatic colorectal cancer (MCRC): results of an international multicenter phase II trial.  Proc Am Soc Clin Oncol. 2002;  21: 133a (Abstr. 531)
• 3 Kerr D J, Ten Bokkel Huinink W W, Ferry D R. et al . A phase I/II study of CPT-11 in combination with capecitabine as first line chemotherapy for metastatic colorectal cancer (MCRC).  Proc Am Soc Clin Oncol. 2002;  21: 161a (Abstr. 643)
• 4 Burris H A, Moore M J, Andersen J. et al . Von HDD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.  J Clin Oncol. 1997;  15 2403-2413
• 5 Cascinu S, Frontini L, Labianca R. et al . A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).  Ann Oncol. 2000;  11 1309-1311
• 6 Di Costanzo F, Sdrobolini A, Carlini P. et al . Gemcitabine (GEM) Alone or in Combination with 5-FU Continuous Infusion (CI) in the Treatment of Advanced Pancreatic Cancer (APC): a GOIRC Randomized Phase II Trial.  Proc Am Soc Clin Oncol. 2001;  20: 154a (Abstr. 612)
• 7 Wein A, Wehler M, Fischer B. et al . Phase II study with weekly 24-hour infusion (24-h inf.) of high-dose 5-fluorouracil (5-FU) and gemcitabine (GEM) in metastatic pancreas cancer (UICC IVb): final results.  Proc Am Soc Clin Oncol. 2002;  21: 156a (Abstr. 620)
• 8 Berlin J D, Catalano P, Thomas J P. et al . Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.  J Clin Oncol. 2002;  20 3270-3275
• 9 Scheithauer W, Schüll B, Ulrich-Pur H. et al . Gemcitabine alone or in combination with capecitabine in patients with advanced pancreatic adenocarcinoma.  Proc Am Soc Clin Oncol. 2002;  21: 126a (Abstr. 500)
• 10 Rocha L CM, Savarese D, Bruckner H. et al . Irinotecan plus gemcitabine induces both radiographic and CA 19 - 9 tumor marker responses in patients with previously untreated advanced pancreatic cancer.  J Clin Oncol. 2002;  20 1182-1191
• 11 Lutz M P, Ducreux M, Wagener T. et al . Docetaxel/gemcitabine or docetaxel/cisplatin in advanced pancreatic carcinoma: a randomized phase II study of the EORTC-GI group.  Proc Am Soc Clin Oncol. 2002;  21: 125a (Abstr. 498)
• 12 Hilgers W, Kern S E. Molecular genetic basis of pancreatic adenocarcinoma.  Genes, Chromosomes & Cancer. 1999;  26 1-12
• 13 Cunningham D, de Gramont A, Scheithauer W. et al . Randomized double-blind placebo-controlled trial of the farnesyltransferase inhibitor R115777 (Zarnestra) in advanced refractory colorectal cancer.  Proc Am Soc Clin Oncol. 2002;  21: 126a (Abstr. 502)
• 14 van Cutsem E, Karasek P, Oettle H. et al . Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer (PC).  Proc Am Soc Clin Oncol. 2002;  21: 130a (Abstr. 517)
• 15 Blanke C D, Benson A B, Dragovich T. et al . A phase II trial of celecoxib (CX) irinotecan (I), 5-fluorouracil (5FU), and leucovorin (LCV) in patients (pts) with unresectable or metastatic colorectal cancer (CRC).  Proc Am Soc Clin Oncol. 2002;  21: 127a (Abstr. 505)
• 16 Schmiegel W, Schmielau J, Henne-Bruns D. et al . Cytokine-mediated enhancement of epidermal growth factor receptor expression provides an immunological approach to the therapy of pancreatic cancer.  Proc Natl Acad Sci USA. 1997;  94 12622-12626
• 17 Bruns C J, Harbison M T, Davis D W. et al . Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.  Clinical Cancer Research. 2000;  6 1936-1948
• 18 Abbruzzese J L, Rosenberg A, Xiong Q. et al . Phase II Study of Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Cetuximab (IMC-C225) in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer.  Proc Am Soc Clin Oncol. 2001;  20: 130a (Abstr. 518)
• 19 Saltz L, Meropol N J, Loehrer P J. et al . Single agent IMC-225 (Erbitux) has activity in CPT-11-refractory colorectal cancer (CRC) that express the epidermal growth factor receptor (EGF-R).  Proc Am Soc Clin Oncol. 2002;  21: 127a (Abstr. 504)
• 20 Rosenberg A H, Loehrer P F, Needle M N. et al . Erbitux (IMC-225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that express the epidermal growth factor receptor (EGF-R).  Proc Am Soc Clin Oncol. 2002;  21: 135a (Abstr. 536)
• 21 Safran H, Ramanathan R K, Schwartz J. et al . Herceptin and Gemcitabine for Metastatic Pancreatic Cancers That Overexpress HER-2/neu.  Proc Am Soc Clin Oncol. 2001;  20: 130a (Abstr. 517)
• 22 Ranson M, Hammond L A, Ferry D. et al . ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.  J Clin Oncol. 2002;  20 2240-2250
• 23 Hidalgo M, Siu L L, Nemunaitis J. et al . Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.  J Clin Oncol. 2001;  19 3267-3279
• 24 von Mehren M, Blanke C, Joensuu H. et al . High incidence of durable responses induced by imatinib mesylate (Gleevec) in patients with unresectable and metastatic gastrointestinal stromal tumors (GISTs).  Proc Am Soc Clin Oncol. 2002;  21: 403a (Abstract. 1608)
• 25 Heinrich M C, Corless C L, Blanke C. et al . KIT mutational status predicts clinical response to STI571 in patients with metastatic gastrointestinal stromal tumors (GISTs).  Proc Am Soc Clin Oncol. 2002;  21: 2a (Abstr. 6)